Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Michael D Pun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [177Lu]Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG4-LLP2A with a 4-(p-iodophenyl)butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [177Lu]Lu-DOTAGA-PEG4-LLP2A ([177Lu]Lu-1) to the albumin binding [177Lu]Lu-DOTAGA-pIBA-PEG4-LLP2A ([177Lu]Lu-2). In vitro cell binding assay results for [177Lu]Lu-1 and [177Lu]Lu-2 showed Kd values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar Bmax values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [177Lu]Lu-2 exhibited a much longer blood circulation time compared to [177Lu]Lu-1. The tumor uptake for [177Lu]Lu-1 was highest at 1 h (∼15%ID/g) and that for [177Lu]Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [177Lu]Lu-1 from the tumor occurs at 24 h (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States.
- Molecular Imaging and Theranostics Center, University of Missouri, Columbia, Missouri 65211, United States.
- Molecular Interactions Core, University of Missouri, Columbia, Missouri 65211, United States.
- Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri 65211, United States.
- University of Missouri Research Reactor Center, University of Missouri, Columbia, Missouri 65211, United States.
- Department of Radiology, University of Missouri, Columbia, Missouri 65212, United States.
ORCID-Profile: Khanh-Van Ho, Carolyn J Anderson
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Pun, M. D., Gallazzi, F., Ho, K. V., Watkinson, L., Carmack, T. L., Iweha, E., Li, L., & Anderson, C. J. (2024). Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00095
Vancouver
Pun MD, Gallazzi F, Ho KV, Watkinson L, Carmack TL, Iweha E, et al. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00095
BibTeX
@article{Pun2024,
author = {Pun, Michael D and Gallazzi, Fabio and Ho, Khanh-Van and Watkinson, Lisa and Carmack, Terry L and Iweha, Ejike and Li, Longbo and Anderson, Carolyn J},
title = {Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00095}
}
EUVIMED